The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer.
 
Thomas J. George
Consulting or Advisory Role - Bayer; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Pharmacyclics (Inst); Tesaro (Inst)
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics; Pharmacyclics
 
James J. Lee
Consulting or Advisory Role - Incyte; Loxo
Research Funding - Incyte; Merck
 
Samuel A. Jacobs
No Relationships to Disclose
 
Melvin Deutsch
No Relationships to Disclose
 
Carmen Joseph Allegra
Honoraria - Bristol-Myers Squibb (I)
 
Norman Wolmark
Research Funding - AbbVie (Inst); AbbVie (Inst); Bayer (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - AbbVie (Inst)
Travel, Accommodations, Expenses - Abbvie; AbbVie; Genentech; GHI Pharma; Sanofi